In this review, we selected seven studies based on systematic reviews, meta-analyses, and randomized clinical trials with a sample size of 508,339 to assess SGLT-2 inhibitors' benefits in patients with cardiovascular diseases. Here, SLC5A2 is linked to cardiovascular disorder.